Menu
1 min read · estimated
APPROVED USE
What FDA approved
Patients with locally advanced basal cell carcinoma after a hedgehog pathway inhibitor, or when that treatment was inappropriate.
LAMPGEN ANALYSIS
Why it matters
The decision brings checkpoint inhibition to locally advanced basal cell carcinoma after or outside use of a hedgehog inhibitor.
What research teams should watch
Capture the prior hedgehog inhibitor or documented reason it was unsuitable and the classification of local disease.
PRIMARY RECORDS